Select Bibliography

Filter by any of these (after searching):

Hoke, E.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 8 items

Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010

Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-10503

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012

Abstract - Primary - Primary - Leukemia - CALGB-10503

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Byrd, J. C. , Lucas, M. S. , Hoke, E. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10101

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - ASH - Blood - 2010

Abstract - Primary - Primary - Leukemia - CALGB-10002

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

Stock, W. , Sanford, B. , Lozanski, G. , Vij, R. , Byrd, J. C. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10102

Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001

Wetzler, M. , Stock, W. , Donohue, K. A. , Owzar, K. , Sher, D. A. ... - - Blood - 2007

Abstract - Primary - Primary - Leukemia - CALGB-10001 , CALGB-8461 , CALGB-9665 , CALGB-9862

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Wetzler, M. , Watson, D. , Stock, W. , Owzar, K. , Koval, G. , Hoke, E. ... - ASH - Blood - 2012

Abstract - Primary - Primary - Leukemia - CALGB-10001